General Internal Medicine

Obesity

Questions discussed in this category

Would you consider pharmacotherapy (i.e., GLP1-agonist) or behavioral/nutrition interventions alone in a patient with a remote history of a restrictive eating disorder now presenting with obesity and metabolic complications?

1 Answer available

How should clinicians balance the use of finerenone with other heart failure treatments like SGLT2 inhibitors, considering their glycemic benefits?

Butt et al., PMID 39818225

2 Answers available

When managing patients with suspected MASLD, what specific criteria or findings would prompt you to refer them to hepatology?

1 Answer available

Papers discussed in this category

European heart journal, 2016-07-14

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.

The New England journal of medicine, 2024 Sep 01

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.

Circulation, 2024 Sep 28

Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.

Related Topics in General Internal Medicine